Decibel Therapeutics Inc. (DBTX) NASDAQ
$4.19 -0.01 (-0.24%)
Market Cap: $104.81M
As of 06/02/23 04:30 PM EDT. Market closed.
Decibel Therapeutics Inc. (DBTX)
NASDAQ
$4.19
-0.01 (-0.24%)
Market Cap: $104.81M
As of 06/02/23 04:30 PM EDT. Market closed.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear ... read more
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Trask Anna | See Remarks | Dec 02, 2021 | Sale | $6.37 | 5,291 | 33,688 | 2,620 | Dec 06, 2021, 04:20 PM |
| Trask Anna | See Remarks | Nov 03, 2021 | Sale | $8.34 | 378 | 3,152 | 7,533 | Nov 04, 2021, 08:00 AM |
| Trask Anna | SEE REMARKS | Nov 02, 2021 | Sale | $8.31 | 4,913 | 40,827 | 7,911 | Nov 03, 2021, 04:16 PM |
| Trask Anna | See Remarks | Oct 14, 2021 | Sale | $7.55 | 5,364 | 40,481 | 12,824 | Oct 15, 2021, 04:57 PM |
| Reid Laurence | President and Chief Executive | Sep 15, 2021 | Buy | $7.64 | 10,000 | 76,400 | 25,849 | Sep 17, 2021, 09:48 PM |
| ORBIMED ADVISORS LLC | Director | Feb 17, 2021 | Buy | $18.00 | 1,666,666 | 29,999,988 | 3,843,206 | Feb 19, 2021, 07:09 PM |
| Foy Matthew | Director | Feb 17, 2021 | Buy | $18.00 | 150,000 | 2,700,000 | 1,183,663 | Feb 19, 2021, 06:59 PM |
| Casdin Partners Master Fund, L.P. | 10% Owner | Feb 17, 2021 | Buy | $18.00 | 575,000 | 10,350,000 | 1,121,421 | Feb 19, 2021, 06:56 PM |
| Thompson Peter A. | Director | Feb 17, 2021 | Buy | $18.00 | 1,666,666 | 29,999,988 | 3,843,206 | Feb 19, 2021, 06:50 PM |
| GLAXOSMITHKLINE PLC | Director | Feb 17, 2021 | Buy | $18.00 | 150,000 | 2,700,000 | 1,183,663 | Feb 19, 2021, 04:50 PM |
| Owner | Relationship | Date | Value($) |
| Trask Anna | See Remarks | 12/02/2021 | 33,688 |
| Trask Anna | See Remarks | 11/03/2021 | 3,152 |
| Trask Anna | SEE REMARKS | 11/02/2021 | 40,827 |
| Trask Anna | See Remarks | 10/14/2021 | 40,481 |
| Reid Laurence | President and Chief Executive | 09/15/2021 | 76,400 |
| ORBIMED ADVISORS LLC | Director | 02/17/2021 | 29,999,988 |
| Foy Matthew | Director | 02/17/2021 | 2,700,000 |
| Casdin Partners Master Fund, L.P. | 10% Owner | 02/17/2021 | 10,350,000 |
| Thompson Peter A. | Director | 02/17/2021 | 29,999,988 |
| GLAXOSMITHKLINE PLC | Director | 02/17/2021 | 2,700,000 |
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 4,945,192 | 0.29% | No change | Other |
| BLACKROCK INC. | 1,806,146 | 0.00016% | 0.06% | Other |
| UBS OCONNOR LLC | 189,386 | 0.03% | 0.76% | Value |
| GEODE CAPITAL MANAGEMENT, LLC | 115,567 | 0.00005% | No change | Other |
| RENAISSANCE TECHNOLOGIES LLC | 32,500 | 0.00013% | -10.7% | Other |
Period of Report: 03/31/2023
10-K/10-Q Filings: View